Targeted next-generation sequencing of circulating free DNA enables non-invasive tumor detection in myxoid liposarcomas
Open accessThe claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In myxoid liposarcoma, combined detection of translocation breakpoints and selected SNVs may improve quantitative monitoring and specificity compared with single-signal approaches.
“In myxoid liposarcoma, combined detection of translocation breakpoints and selected SNVs may improve quantitative monitoring and specificity compared with single-signal approaches [ 35 ].”
From Signals Alongside Scans: A Genomics-Guided Framework for Liquid Biopsy in Bone and Soft-Tissue Sarcomas (2026) · cites this paper as [35]
Synovial sarcoma and myxoid liposarcoma illustrate the value of structural-variant or breakpoint-informed approaches.
“Synovial sarcoma and myxoid liposarcoma similarly illustrate the value of structural-variant or breakpoint-informed approaches, although available cohorts remain limited and assay standardization is still needed [ 14 , 15 , 24 , 35 ].”
From Signals Alongside Scans: A Genomics-Guided Framework for Liquid Biopsy in Bone and Soft-Tissue Sarcomas (2026) · cites this paper as [35]
Commercial or large-panel plasma profiling may identify clinically relevant alterations in selected advanced cases.
“Commercial or large-panel plasma profiling may identify clinically relevant alterations in selected advanced cases, but variable tissue–plasma concordance, low tumor fraction, and inconsistent copy-number detection limit its use as a general surveillance strategy [ 32 , 33 , 34 , 35 , 36 ].”
From Signals Alongside Scans: A Genomics-Guided Framework for Liquid Biopsy in Bone and Soft-Tissue Sarcomas (2026) · cites this paper as [35]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Alpelisib for <i>PIK3CA</i> -Mutated, Hormone Receptor–Positive Advanced Breast Cancer
André, F., Ciruelos, E., Rubovszky, G., Campone, M., Loibl, S., Rugo, H. S., Iwata, H., Conte, P., Mayer, I. A., Kaufman, B., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1813904 · Cited by 2,622 · see citing works
Bratman, S. V., Yang, S. Y. C., Iafolla, M. A. J., Liu, Z., Hansen, A. R., Bedard, P. L., Lheureux, S., Spreafico, A., Razak, A. A., Shchegrova, S., et al. (2020) · Nature Cancer · doi:10.1038/s43018-020-0096-5 · Cited by 487 · see citing works
MacConaill, L. E., Burns, R., Nag, A., Coleman, H. A., Slevin, M. K., Giorda, K., Light, M., Lai, K., Jarosz, M., McNeill, M., et al. (2018) · BMC Genomics · doi:10.1186/s12864-017-4428-5 · Cited by 238 · see citing works
A mathematical model of ctDNA shedding predicts tumor detection size
Avanzini, S., Kurtz, D. M., Chabon, J. J., Moding, E. J., Hori, S. S., Gambhir, S. S., Alizadeh, A. A., Diehn, M., & Reiter, J. G. (2020) · Science Advances · doi:10.1126/sciadv.abc4308 · Cited by 214 · see citing works
Movva, S., Wen, W., Chen, W., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3498 · Cited by 129 · see citing works
Exomic analysis of myxoid liposarcomas, synovial sarcomas, and osteosarcomas
Joseph, C. G., Hwang, H., Jiao, Y., Wood, L. D., Kinde, I., Wu, J., Mandahl, N., Luo, J., Hruban, R. H., Diaz, L. A., et al. (2013) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22114 · Cited by 109 · see citing works
Koelsche, C., Renner, M., Hartmann, W., Brandt, R., Lehner, B., Waldburger, N., Alldinger, I., Schmitt, T., Egerer, G., Penzel, R., et al. (2014) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-33-33 · Cited by 98 · see citing works
Myxoid liposarcoma: local relapse and metastatic pattern in 43 patients
Dürr, H. R., Rauh, J., Baur‐Melnyk, A., et al. (2018) · BMC Cancer · doi:10.1186/s12885-018-4226-8 · Cited by 88 · see citing works
Muratori, F., Bettini, L., Frenos, F., et al. (2018) · International Journal of Surgical Oncology · doi:10.1155/2018/8928706 · Cited by 68 · see citing works
PET/CT imaging for tumour response assessment to immunotherapy: current status and future directions
Unterrainer, M., Ruzicka, M., Fabritius, M. P., Mittlmeier, L. M., Winkelmann, M., Rübenthaler, J., Brendel, M., Subklewe, M. S., von Bergwelt‐Baildon, M., Ricke, J., et al. (2020) · European Radiology Experimental · doi:10.1186/s41747-020-00190-1 · Cited by 64 · see citing works
Genotyping of circulating cell-free DNA enables noninvasive tumor detection in myxoid liposarcomas
Braig, D., Becherer, C., Bickert, C., Braig, M., Claus, R., Eisenhardt, A. E., Heinz, J., Scholber, J., Herget, G. W., Bronsert, P., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32216 · Cited by 42 · see citing works
Self-citationDifferent patterns of clonal evolution among different sarcoma subtypes followed for up to 25 years
Hofvander, J., Viklund, B., Isaksson, A., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06098-0 · Cited by 28 · see citing works
Multifocal Myxoid Liposarcoma—Metastasis or Second Primary Tumor?
de Vreeze, R. S. A., de Jong, D., Nederlof, P. M., et al. (2010) · Journal of Molecular Diagnostics · doi:10.2353/jmoldx.2010.090117 · Cited by 19 · see citing works
Ferreira, M. S. V., Crysandt, M. M., Braunschweig, T. A., Jost, E., Voss, B., Bouillon, A., Knuechel, R., Brümmendorf, T. H., & Beier, F. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19020608 · Cited by 18 · see citing works
Xiang, H., Wang, J., Hisaoka, M., et al. (2008) · Pathology · doi:10.1080/00313020802320424 · Cited by 17 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Genotyping of Circulating Free DNA Enables Monitoring of Tumor Dynamics in Synovial Sarcomas
Eisenhardt, A. E., Brugger, Z., Lausch, U., Kiefer, J., Zeller, J., Runkel, A., Schmid, A., Bronsert, P., Wehrle, J., Leithner, A., et al. (2022) · Cancers · doi:10.3390/cancers14092078 · Cited by 18 · see citing works
Self-citationSchmid, A., Lausch, U., Runkel, A., Kiefer, J., Pauli, T., Boerries, M., Bogner, B., Eisenhardt, S. U., & Braig, D. (2025) · Cancer Medicine · doi:10.1002/cam4.70704 · Cited by 4 · see citing works
Self-citationAlabid, I., Yousef, A. J., Patni, M. M., Aloti, R. A., Qassim, Z. A.-A. M., Alothman-Agha, A. A., Hamdy, H. A., Noury, F. M., & Abdelfattah, M. T. (2026) · Cells · doi:10.3390/cells15141271
- Authors
- Eisenhardt, A. E., Schmid, A., Esser, J., Brugger, Z., Lausch, U., Kiefer, J., Braig, M., Runkel, A., Wehrle, J., Claus, R., Bronsert, P., Leithner, A., Liegl-Atzwanger, B., Zeller, J., Papini, R., von Laffert, M., Pfitzner, B. M., Koulaxouzidis, G., Giunta, R. E., Eisenhardt, S. U., & Braig, D.
- Affiliations
- University of Freiburg (DE)
- University of Augsburg (DE)
- Medical University of Graz (AT)
- Sir Charles Gairdner Hospital (AU)
- DRK Kliniken Berlin (DE)
- Charité – Universitätsmedizin Berlin (DE)
- LMU Klinikum (DE)
- Corresponding author
- Braig, David
- ORCID
- Venue
- Molecular Cancer
- Published
- 2022-02-14
- Volume
- 21
- Issue
- 1
- Pages
- 50-50
- ISSN
- 1476-4598 (ISSN-L)
- PMC
- PMC8842903
- OpenAlex
- W4213282197
- Cited by
- 10
- References
- 15
- Citations by year
- 2026: 2 · 2025: 5 · 2023: 1 · 2022: 2
- FWCI
- 0.84
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Molecular Cancer (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- OPUS (Augsburg University) (submittedVersion, cc-by)
- Funders
- Deutsche Forschungsgemeinschaft (396168587)
- Universität Heidelberg
- Göteborgs Universitet
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Sarcoma Diagnosis and Treatment
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Prenatal Screening and Diagnostics
- Keywords
- myxoid liposarcoma, cell-free DNA, liquid biopsy, non-invasive cancer detection, targeted next-generation sequencing
- MeSH terms
- Cell-Free Nucleic Acids, DNA, Humans, Neoplasms, Biomarkers, Tumor, Liposarcoma, Myxoid, High-Throughput Nucleotide Sequencing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
